Curis holds $5.0m in cash as emavusertib trials press on towards December data

Curis has a thin financial cushion and a lot riding on one drug. The US oncology company reported a third-quarter 2026 net loss of $8.1 million on 12 November, alongside cash of $5.0 million. It says its funding now lasts only into the first quarter of 2027.

The company points to two financings behind that outlook: a public offering in August 2026 and a private placement in October 2026 worth about $7.5 million. The facts provided do not say how the October proceeds relate to the reported cash balance, nor give any detail on the terms of either deal.

The funding supports emavusertib, a drug that inhibits both IRAK4 and FLT3. It is being tested in chronic lymphocytic leukaemia (CLL) with zanubrutinib, a BTK inhibitor. Twelve patients are enrolled so far, and Curis expects its first data from that combination in December 2026. A cohort that small points to an early look at the regimen rather than a conclusive efficacy readout.

In relapsed or refractory primary central nervous system lymphoma (PCNSL), emavusertib is being studied with another BTK inhibitor, ibrutinib. Curis says the US FDA and the European Medicines Agency's CHMP told it in 2025 that the planned registrational study could underpin applications for accelerated approval. By way of general context, such pathways permit conditional authorisation on surrogate or intermediate endpoints, typically with confirmatory evidence required afterwards. The regulators' advice is as described by the company.